bioRxivBiophysicsPreprint
Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin
J. Li, X. Zhou, Y. Zhang, F. Zhong, C. Lin, P. J. McCormick, F. Jiang, H. Zhou, Q. Wang, J. Duan, J. Zhang
Abstract
Main protease (Mpro, also known as 3CLpro) has a major role in the replication of coronavirus life cycle and is one of the most important drug targets for anticoronavirus agents. Here we report the crystal structure of main protease of SARS-CoV-2 bound to a previously identified Chinese herb inhibitor shikonin at 2.45 angstrom resolution. Although the structure revealed here shares similar overall structure with other published structures, there are several key differences which highlight potential features that could be exploited. The catalytic dyad His41-Cys145 undergoes dramatic conformational changes, and the structure reveals an unusual arrangement of oxyanion loop stabilized by the substrate. Binding to shikonin and binding of covalent inhibitors show different binding modes, suggesting a diversity in inhibitor binding. As we learn more about different binding modes and their structure-function relationships, it is probable that we can design more effective and specific drugs with high potency that can serve as effect SARS-CoV-2 anti-viral agents.
- organism: virus
- assay: protein structure
- research focus: protein structure prediction
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inhibitor Binding Modulates Protonation States in the Active Site of SARS-CoV-2 Main Protease
D. W. Kneller, G. Phillips, … A. Kovalevsky·bioRxiv·Jan 12, 2021
- A novel conformational state for SARS-CoV-2 main protease
E. Fornasier, M. L. Macchia, … R. Battistutta·bioRxiv·Mar 4, 2021
- An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity
N. Kitamura, M. D. Sacco, … J. Wang·bioRxiv·Dec 19, 2020
- Inhibitor binding influences the protonation states of histidines in SARS-CoV-2 main protease
A. Pavlova, D. L. Lynch, … J. C. Gumbart·bioRxiv·Sep 7, 2020
- Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases
M. Westberg, Y. Su, … M. Lin·bioRxiv·Sep 15, 2020
- Discovery of Potent Pyrazoline-Based Covalent SARS-CoV-2 Main Protease Inhibitors
P. Moon, L. Boike, … D. K. Nomura·bioRxiv·Mar 5, 2022